About Us

Our team is united in a mission to advance cancer care and offer new hope to patients.

We Shift the 
Cancer Care Paradigm

The pioneering team at Surefire Medical is inventing the future for cancer care. We develop advanced liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries paired with new, precise technology arm physicians to harness infusion pressure and work with the body’s natural flow, targeting tumors with superior accuracy, control and protection.

Our founders, a biomedical engineer and an Interventional Radiologist, established Surefire Medical to revolutionize cancer treatment. Our inventive device technology is designed by and for the IR community by a Colorado-based team of physicians, engineers and researchers. We seek clinical discoveries and create new technologies with one goal in mind: to deliver improved outcomes for cancer patients and their families.

Meet the Team

Board of Directors

mats2

Mats L. Wahlström

Chairman
mats2

Mats L. Wahlström
Chairman

Mr. Wahlström has more than 30 years of experience in the healthcare industry, having served as CEO and CFO of large international companies in the renal field. Mats currently serves as Executive Chairman of KMG Capital Partners, LLC, Chairman of PCI | HealthDev, and Chairman of Caduceus Medical Holdings, Inc. He also serves as the Lead Director and Chairman of the Audit/Finance Committee of Coherus Biosciences, a public biotech company. In addition, he currently serves on the boards of Getinge AB and Alteco Medical AB, both public companies, as well as Triomed AB and Circuit Clinical, Inc.

Mats served as a director of Health Grades, Inc., a NASDAQ-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010. From January 2004 through December 2009, Mats served as Co-CEO of Fresenius Medical Care North America and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, which operates more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including President and CEO of Gambro North America as well as CFO of the Gambro Group.

karen

Karen Cassidy

Director
karen

Karen Cassidy
Director

Ms. Cassidy began her career in a start-up at Johnson & Johnson, the Dermatological Division. She spent six years at Xerox, initially as Sales Operation Planning Manager for the U.S., then running worldwide operations for this function, followed by a two-year stint in the field as a Sales Manager. After this operating background, Ms. Cassidy joined Oak Investment Partners for seven years and subsequently co-managed Aetna’s Venture Capital Fund. Ms. Cassidy then returned to the operating side in 1991, assuming the CEO role at ImplaMed and VP Business Development roles at Symbiosis and Corvita, which were sold within a seven-year period. As Managing Director at Partisan Management, Ms. Cassidy has recruited and mentored the management team for each company and applied her sales, marketing, and business development expertise to the building of the company. Ms. Cassidy also manages the liquidity events for the Partisan Management companies.

james

James E. Chomas, PhD

Director
james

James E. Chomas, PhD
Director

Dr. Chomas has more than 15 years of experience in developing devices from initial concept through clinical trials and has served in leadership positions in both public and venture-backed companies. He co-founded Surefire Medical in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Dr. Chomas is an active member of the growing biosciences community in Colorado, serving on the board of Colorado Biosciences Association (CBSA) as well as working with the Colorado Office of Economic Development and International Trade (OEDIT) to review early stage funding opportunities. He received his Bachelor of Science degree in Engineering from Duke University and completed his doctoral training at the University of Virginia, investigating the use of ultrasound in breast cancer characterization. Since moving from academics to industry, Dr. Chomas has focused his career on finding better ways to detect and treat cancer. In addition, he has authored more than 25 medical device patents.

ginger

Ginger L. Graham

Director
ginger

Ginger L. Graham
Director

Ginger Graham is a recognized biopharmaceutical and medical device leader with more than 30 years experience. She teaches a course in entrepreneurship at the Harvard Business School and consults to first-time CEO’s in the areas of leadership, strategy, board-effectiveness, and organization-building.

Ms. Graham is the former President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on diabetes and obesity. Prior to her time at Amylin, she was Group Chairman, Office of the President for Guidant Corporation, a major cardiovascular medical device manufacturer based in Indianapolis, IN. She started her career in healthcare at Eli Lilly and Company in a variety of roles.

Ms. Graham serves on the Boards of Directors for Walgreen Co., Genomic Health, Inc., Proteus Biomedical, Surefire Medical, and the American Diabetes Association Research Foundation, where she serves as Vice Chair. Ms. Graham received a Bachelor of Science degree in agricultural economics from the University of Arkansas, and holds an MBA degree, with distinction, from Harvard University.

beverly

Beverly Huss, MS

Director
beverly

Beverly Huss, MS
Director

Beverly Huss, currently President and CEO of Qool Therapeutics, has more than 30 years of experience in the medical industry. Prior to joining Qool, Ms. Huss was President and CEO of Vibrynt, Inc., a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity.  While at Guidant for more than 19 years, Ms. Huss fulfilled a variety of executive roles within the company’s various medical device divisions, including serving as President of the worldwide Endovascular Solutions business where worldwide revenues quadrupled to $150 million for the carotid and peripheral vascular business in four years. In addition, Ms. Huss built Guidant’s coronary stent business, the market leader for 27 of 28 quarters.

Earlier in her career, Ms. Huss held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel.  Additionally, she served as chair of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA- based cell therapy company.  Ms. Huss holds an M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois.  She has several patents to her credit in the cardiovascular and obesity medical device areas.

mark

Mark Lupa

Director
mark

Mark Lupa
Director

Dr. Lupa holds a Bachelor’s of Science degree from Northwestern University, a Master’s degree from the University of Sussex (England) in Biomedical Engineering and completed his doctoral program in Pharmacology from the University of Lund, Sweden. He conducted neuroscience research for 15 years at institutions worldwide, including the University of Colorado and the University of California San Francisco. Dr. Lupa’s business experience came first in the brewing industry as founder, CEO and CFO of Tabernash Brewing Company, which was formed in 1993 and merged with Left Hand Brewing in 1998. Dr. Lupa then moved to the private investment company Tango to focus on technology and Life Science investments. He is currently Managing Director of High Country Venture, a venture capital fund in Boulder, Colorado, and has served as founding member of the Board of Directors of Taligen Therapeutics, Sierra Neuropharma, Oberon, DCS Surgical, and Theratogs. Dr. Lupa also served as CFO of Taligen from inception of the company in 2004 until early 2008.

gene

Gene McGrevin

Director
gene

Gene McGrevin
Director

With more than 25 years of experience in the medical industry, Gene McGrevin has held senior management positions in global companies including Johnson & Johnson and Kimberly-Clark Corporation. Mr. McGrevin also was instrumental in the expansion and sale of several medical startups.  They include PetNet Pharmaceuticals (sold to Siemens), Microtek Medical Holdings (sold to EcoLabs), and Medivance (sold to C.R. Bard).  In addition, Mr. McGrevin serves on the Boards of the Yerkes Primate Center, Real Time Medical Data and HydroDynamics. Mr. McGrevin holds an MBA from the University of Pennsylvania’s Wharton School.  He earned a BA in economics at the University of Pittsburgh.

john-t

John L. Tullis

Director
john-t

John L. Tullis
Director

Mr. Tullis is President and a Partner at Tullis Health Investors, where he is focused especially on healthcare technology and services, medical devices, and international markets.  He has more than 19 years of investing and international business experience.  Mr. Tullis currently serves as Chairman of CareSync, Inc. and was also an Executive Committee Member of the Board of Directors of the Beacon Council, Miami-Dade’s Economic Development Organization, for three years.

Mr. Tullis hold a Bachelor’s degree in Liberal Arts from DePauw University.  He received a Graduate Certificate from the University of Virginia’s McIntire Business Institute, and a Master’s degree in Business Administration from the University of Miami.  At ages 14-15, he studied at a Taiwanese boarding school, where he was the school’s only non-Chinese student.

norman

Norman Weldon

Director
norman

Norman Weldon
Director

Dr. Weldon is a highly experienced medical device leader with a track record of success at the highest business and operational levels. Dr. Weldon’s background is in economics, technology and general management. He has been the CEO of three public companies: CTS Corporation (NYSE CTS), Cordis Corporation (NASDAQ CORD) and Corvita Corporation (NASDAQ CVTA). He was a co-founder of CTS Microelectronics, Inc., Corvita Corporation, Novoste Puerto Rico, Inc., Novoste Corporation, Enable Medical Corporation, AtriCure, Inc., Medivance, Inc. and Neuronetics, Inc. As the Chairman of the Board, Dr. Weldon provides key guidance in all aspects of the company, sharing his wealth of knowledge, experience, and network of talent.

Management Team

james

James E. Chomas, PhD

Founder, CEO & President
james

James E. Chomas, PhD
Founder, CEO & President

Dr. Chomas has more than 15 years of experience in developing devices from initial concept through clinical trials and has served in leadership positions in both public and venture-backed companies. He co-founded Surefire Medical in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Dr. Chomas is an active member of the growing biosciences community in Colorado, serving on the board of Colorado Biosciences Association (CBSA) as well as working with the Colorado Office of Economic Development and International Trade (OEDIT) to review early stage funding opportunities. He received his Bachelor of Science degree in Engineering from Duke University and completed his doctoral training at the University of Virginia, investigating the use of ultrasound in breast cancer characterization. Since moving from academics to industry, Dr. Chomas has focused his career on finding better ways to detect and treat cancer. In addition, he has authored more than 25 medical device patents.

aravind

Aravind Arepally, MD, FSIR

Founder
aravind

Aravind Arepally, MD, FSIR
Founder

Dr. Arepally has extensive expertise with both the clinical and research aspect of embolotherapy. Having 10 years of experience in clinical interventional radiology, he has performed more than 500 embolotherapy cases while on faculty at Johns Hopkins Medical Institutes. In addition, Dr. Arepally has led a research lab at JHU focused on the development of embolic beads for targeted delivery, and is currently in clinical practice at Piedmont Hospital. Dr. Arepally provides a critical link for the clinical and technical needs and demands of a microcatheter.

Dr. Arepally obtained his mathematics degree from Mercer University. He went on to obtain his MD at Emory University School of Medicine and continued residency and chief residency in Radiology at Emory University Hospital. He went to Johns Hopkins for additional training in Interventional Radiology and joined the faculty in 2000. From 2007 to 2009, Aravind was the Clinical Director for the Center for Bioengineering Innovation and Design, with a research focus on the development of targeted drug and cellular delivery to treat diabetes and obesity. He has authored more than 150 papers, books, and abstracts, and has been a principal investigator or co-investigator on more than 15 grants (5 NIH). Dr. Arepally is the recipient of numerous national awards and grants for his research in the field of MRI and device development.

Anthony

Anthony Scalese

Chief Financial Officer
Anthony

Anthony Scalese
Chief Financial Officer

With more than 16 years of experience in accounting, finance, operations and mergers and acquisitions, Mr. Scalese has spent the past 15 years of his career in the high-tech and healthcare industries. He recently served as CFO for Novinda Corp., a clean tech, startup company specializing in air quality control. In addition, Mr. Scalese served as CFO of Zynex Medical, a global medical device manufacturer and CFO of Qualmark Corporation, a publicly held global manufacturer of durability testing equipment. While at Qualmark, he served as President for various subsidiaries as well. He also held positions at Coram Healthcare (now Apria Healthcare), Foundation Health Systems (now Healthnet) and Coca-Cola Enterprises. Mr. Scalese is a Certified Public Accountant licensed in Colorado, received a Master of Business Administration degree from the University of Colorado and a Bachelor of Science degree in Business Administration (Accounting) from Colorado State University.

stephen

Stephen Cambridge

VP of Sales, Outside the U.S.
stephen

Stephen Cambridge
VP of Sales, Outside the U.S.

Mr. Cambridge brings 25 years of experience in sales, training, recruiting, management and marketing in the pharmaceutical and medical device markets for both large and start-up companies. Mr. Cambridge has deep medical device sales experience with winning organizations such as Cordis Corporation, DVI, Inc., Cook, Inc., AVE, Inc., and AtriCure, Inc. As Director of Sales for AtriCure, Inc., Mr. Cambridge built a 20-person sales team who achieved $20 million in revenue in the company’s first two years. Two years later, as Vice President of Sales for AtriCure, Inc., Mr. Cambridge led a team of 40 sales representatives to achieve yearly revenue sales of $39 million. Mr. Cambridge has been a member of three successful start-up companies that were either acquired or went public. Possessing a passion for teamwork, he is highly experienced in building a dedicated, motivated, and results-driven sales force.

lori

Lori Ann Santamaria

VP of Operations
lori

Lori Ann Santamaria
VP of Operations

Ms. Santamaria has experience bringing multiple products to market from concept through commercialization including initial prototyping, pre-clinical testing and design validation. She began her career at Cordis Neurovascular, part of Johnson and Johnson. During her tenure there she held positions in research and development, production and marketing. She led the development of microcatheters for both the neurovascular and peripheral markets. She subsequently managed the global product launch, including training the sales force in the U.S., Latin America, Europe and Asia. Most recently she was the Director of Product Development for OrbusNeich Medical, Inc., where she was responsible for the commercialization of a combination stent platform which required a 180 patient randomized clinical trial. There Ms. Santamaria also led the development and transfer of manufacturing process to plants outside the U.S. Ms. Santamaria received her undergraduate degree from the University of Florida and is currently pursuing her MBA with a specialization in Health Sector Management and Policy from the University of Miami.

rebecca

Rebecca Offner

Director of Clinical Affairs
rebecca

Rebecca Offner
Director of Clinical Affairs

Rebecca (Donzanti) Offner has been in the medical device industry for 27 years. She has worked in clinical services, sales, clinical personnel management, product development, product clinical validation and clinical research monitoring. Ms. Offner has excelled in bringing innovative technology from the bench to active clinical use. She most recently came from Medivance/Bard where she worked closely with engineering during product development and successfully introduced new technology to national and international clinical experts. Her market development skills led to tremendous growth in both the domestic and international markets. She graduated from Widener University and received her Master’s degree from the University of Pennsylvania.

lynne

Lynne Aronson

VP of Regulatory and Quality
lynne

Lynne Aronson
VP of Regulatory and Quality

Ms. Aronson has 25 years of experience in the medical device industry, focusing on domestic and international regulatory affairs, quality assurance and clinical research in temperature management, interventional cardiology, hemodialysis and orthopedics. For the past 11 years, Ms. Aronson was the Director of RA/QA at Medivance, Inc. (C.R. Bard). Additionally, she has held positions at Global Therapeutics (Cook), COBE Renal Care (Gambro), Acufex Microsurgical (Smith & Nephew), Medical Device Consultants, Inc., and Duke University Medical Center. Ms. Aronson received a Bachelor’s of Science in Biomedical Engineering from Duke University.

karen

Karen Cassidy

VP of Business Development
karen

Karen Cassidy
VP of Business Development

Ms. Cassidy began her career in a start-up at Johnson & Johnson, the Dermatological Division. She spent six years at Xerox, initially as Sales Operation Planning Manager for the U.S., then running worldwide operations for this function, followed by a two-year stint in the field as a Sales Manager. After this operating background, Ms. Cassidy joined Oak Investment Partners for seven years and subsequently co-managed Aetna’s Venture Capital Fund. Ms. Cassidy then returned to the operating side in 1991, assuming the CEO role at ImplaMed and VP Business Development roles at Symbiosis and Corvita, which were sold within a seven-year period. As Managing Director at Partisan Management, Ms. Cassidy has recruited and mentored the management team for each company and applied her sales, marketing, and business development expertise to the building of the company. Ms. Cassidy also manages the liquidity events for the Partisan Management companies.

riley

Riley Kyle

Controller
riley

Riley Kyle
Controller

Mr. Kyle has more than 30 years of experience in financial and management positions in the medical device, technology and transportation industries. Focusing in the areas of general ledger control, budgeting, cash management, financial reporting, systems and process improvements, he served as Controller at Medivance, Accounting Services Manager for Rogue Wave, and Accounting Operation Manager for Ryder Transportation. Mr. Kyle received his bachelor’s degree from University of Colorado at Boulder.

Corey

Corey Griffin

Director of Training and Sales Operations
Corey

Corey Griffin
Director of Training and Sales Operations

Ms. Griffin has more than 15 years of experience in sales and customer service.  She joined the Surefire Medical team in 2012 and has managed customer service, human resources, worldwide sales operations and the per diem team. As Director of Training and Sales Operations, Ms. Griffin also took on the added responsibility of managing the entire clinical team and implementing and executing training for the worldwide sales team.  Before joining Surefire, Ms. Griffin served as director of customer relations for a construction company, taught elementary school and served as director of admissions at an independent pre-K through ninth grade school.  She earned her Bachelor of Science in Business Administration from the University of Denver and a Master of Education degree from Christian Brothers University.

amy

Amy Davelle

VP of Sales, North America
amy

Amy Davelle
VP of Sales, North America

Ms. Davalle is a seasoned medical device executive with more than 25 years of experience who is passionate about high growth, complex medical markets. She has held various positions of increasing responsibility from top sales professional to leading a high performing team of more than 135 sales professionals as VP of Sales. During her time at Guidant/Boston Scientific, she was responsible for the integration strategy of Maquet Cardiovascular following the acquisition. Ms. Davalle served as regional VP of Sales at Smith and Nephew as well as the VP of Sales for the medical start-up company MedicalCue. Ms. Davalle is known for her strong sales acumen and her ability to navigate the healthcare landscape of Group Purchasing Organizations, Integrated Delivery Networks and Accountable Care Organizations. She received her Bachelor of Science degree from University of Wisconsin-Milwaukee and a Master’s of Business Administration from Northwestern University, Kellogg School of Management.

Scientific Advisory Board

aravind

Aravind Arepally, MD, FSIR

Chairman, Piedmont Hospital
aravind

Aravind Arepally, MD, FSIR
Chairman, Piedmont Hospital

Dr. Arepally has extensive expertise with both the clinical and research aspect of embolotherapy. Having 10 years of experience in clinical interventional radiology, he has performed more than 500 embolotherapy cases while on faculty at Johns Hopkins Medical Institutes. In addition, Dr. Arepally has led a research lab at JHU focused on the development of embolic beads for targeted delivery, and is currently in clinical practice at Piedmont Hospital. Dr. Arepally provides a critical link for the clinical and technical needs and demands of a microcatheter.

Dr. Arepally obtained his mathematics degree from Mercer University. He went on to obtain his MD at Emory University School of Medicine and continued residency and chief residency in Radiology at Emory University Hospital. He went to Johns Hopkins for additional training in Interventional Radiology and joined the faculty in 2000. From 2007 to 2009, Aravind was the Clinical Director for the Center for Bioengineering Innovation and Design, with a research focus on the development of targeted drug and cellular delivery to treat diabetes and obesity. He has authored more than 150 papers, books, and abstracts, and has been a principal investigator or co-investigator on more than 15 grants (5 NIH). Dr. Arepally is the recipient of numerous national awards and grants for his research in the field of MRI and device development.

charles

Charles Nutting, DO

Sky Ridge Medical Center
charles

Charles Nutting, DO
Sky Ridge Medical Center

Dr. Nutting completed his undergraduate education at Loyola University of Chicago and a D.O. from Chicago College of Osteopathic Medicine. He went on to complete his residency at Olympia Fields Hospital in Diagnostic Radiology, followed by a fellowship in Interventional Radiology at Rush-Presbyterian-St. Luke’s Medical Center in Chicago. Dr. Nutting served as the Chief of Interventional Radiology at Good Samaritan Regional Medical Center and is currently the Chief of Interventional Radiology at Radiology Imaging Associates, and he performs procedures at Sky Ridge Medical Center and Swedish Medical Center in Colorado. Dr. Nutting has been a leading practitioner and clinical researcher in radioembolization, and through his leadership, Sky Ridge is a SirTex Center of Excellence for radioembolization procedures. Dr. Nutting is an active member of the Society of Interventional Radiologists, chairs the practice development subcommittee and is a proctor for SirTex radioembolization procedures throughout the U.S.

leonard

Leonard Pinchuk, PhD

CEO, Innovia LLC
leonard

Leonard Pinchuk, PhD
CEO, Innovia LLC

Dr. Pinchuk is the Co-founder, President, and CEO of Innovia. As an inventor with a background in Chemistry, Engineering and Medicine, he initiates and oversees all projects, and also provides substantial product and process development input.

Dr. Pinchuk is a world-renowned expert in the field of biomaterials and medical devices with more than 80 patents in this area. His accomplishments include the invention of the nylon angioplasty balloon, which has now become the world’s most popular angioplasty balloon, marketed by Cordis Corporation, Boston Scientific Corporation (“BSC”), and Guidant Corporation; a flexible coronary stent; the family of polycarbonate urethane biomaterials for implantation applications; and polyurethane-based vascular grafts and stent-grafts, including the first modular bifurcated stent-graft for treating abdominal aortic aneurysms. Dr. Pinchuk’s most notable achievement has been the development of a novel family of biocompatible elastomeric copolymers. Specific formulations of this polymer have enabled the next generation of coronary stents, namely the Boston Scientific Taxus® Stent, where drugs can be released from these devices to inhibit restenosis.

ryan

Ryan N. Majoria, MD

Our Lady of the Lake Regional Medical Center
ryan

Ryan N. Majoria, MD
Our Lady of the Lake Regional Medical Center

Dr. Majoria pursued a chemistry degree at the University of New Orleans in 1984 for his undergraduate education where he received academic and track and field scholarships, as well as the Rene and Glorain Scholarship for Cancer Research in 1986. He was accepted early into Louisiana State University Medical School in New Orleans during his third year of college in 1987, and decided to forego his college degree to pursue his medical career. After receiving his medical degree in 1991, Majoria completed his internship in Internal Medicine at the Alton Ochsner Medical Foundation in New Orleans in 1992 and pursued his diagnostic and interventional radiology residency at the University of South Alabama Medical Center in Mobile, Alabama. He received his Board Certification in 1996.

Dr. Majoria then began his private practice career in Baton Rouge, Louisiana performing mostly interventional radiology at the largest non-charity hospital in the state at Our Lady of the Lake Regional Medical Center. In early 2000, he became Chief of Interventional Radiology and Interventional Oncology. With his early acceptance of newer minimally invasive techniques, such as arterial embolization and radiofrequency ablation, the interventional radiology practice grew exponentially.

fred

Fred Moeslein, MD, PhD

University of Maryland Medical Center
fred

Fred Moeslein, MD, PhD
University of Maryland Medical Center

Dr. Moeslein received his undergraduate degree in Biochemistry from Case Western Reserve University and his medical and doctoral degrees from Case Western Reserve University. He completed a residency in diagnostic radiology at The Cleveland Clinic and a fellowship in vascular and interventional radiology at The University of Maryland. After the completion of these residencies, Dr. Moeslein served as Assistant Professor of Radiology at the University of Pittsburgh, before returning to the University of Maryland School of Medicine. He currently serves as Interim Director, Division of Vascular and Interventional Radiology at the University of Maryland School of Medicine. Dr. Moeslein is a member of several organizations, including the Society of Interventional Radiology, the American Medical Association, the American Academy of Sciences, the Radiological Society of North America, Inc., and the Cardiovascular and Interventional Radiological Society of Europe. His research interests including Selective Internal Radiotherapy in the management of both primary and metastatic hepatic malignancies, Image guidance for percutaneous procedures, and novel management strategies for painful bony metastases.

gordon

Gordon McLennan, MD

The Cleveland Clinic
gordon

Gordon McLennan, MD
The Cleveland Clinic

Dr. McLennan received his undergraduate degree from Johns Hopkins University and his medical degree from Virginia Commonwealth University Medical College. Following an internship and residency in general surgery at Mercy Catholic Medical Center in Philadelphia, he completed a Fellowship in Interventional Radiology at the Indiana University Hospital. Dr. McLennan, author of more than 34 published articles, serves as Past Chair of the Society of Interventional Radiology (SIR) Foundation. He is a member of the Board of Trustees of The Renal Network, Inc., and is a member of the Radiological Society of North America, the Society of Interventional Radiology, the Cardiovascular and Interventional Radiology Society of Europe, the American Chemical Society and the Association of University Radiologists. (Dr. McLennan will receive stock options as a member of Surefire’s SAB.)

john-d

John R. Daniels, MD

USC Norris Comprehensive Cancer Center and Hospital
john-d

John R. Daniels, MD
USC Norris Comprehensive Cancer Center and Hospital

John R. Daniels, M.D. is a former chief executive officer and chairman at a number of medical technology companies, as well as an accomplished clinician and past faculty member of the Stanford University School of Medicine. From 1990 to the present, Dr. Daniels has served as an associate professor of medicine in the Division of Oncology at the University of Southern California School Of Medicine. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Daniels has authored more than 100 peer-reviewed articles, book chapter and abstracts for influential medical journals. A graduate of Stanford University’s School of Medicine, Dr. Daniels has been a faculty member at the Keck School of Medicine since 1979.  Dr. Daniels is the founder or co-founder of five start-up companies, including Collagen Corporation (acquired by Inamed), Target Therapeutics (acquired by Boston Scientific Corporation), and Balance Pharmaceuticals.  From 1997 until 2002, Dr. Daniels was Chairman of Cohesion Technologies (acquired by Angiotech Pharmaceuticals). Dr. Daniels holds a B.A. from Stanford University and an M.D. from the Stanford University School of Medicine.

steven-k

Steven Katz, MD, FACS

Roger Williams Medical Center & Boston University Medical Center
steven-k

Steven Katz, MD, FACS
Roger Williams Medical Center & Boston University Medical Center

Dr. Katz attended the New York University School of Medicine, receiving the Alpha Omega Alpha Award for graduating with the top academic average in his class. He completed his general surgery residency at the New York University Medical Center. Dr. Katz completed Fellowships in Immunology and Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow.  His clinical expertise is in liver surgery, pancreatic surgery, sarcoma, and melanoma. His laboratory research endeavors focus on immunotherapy for liver metastases and sarcoma.  He was the principal investigator for the Hepatic Immunotherapy for Metastases (HITM) trial, which tested regional infusion of genetically modified T cells for liver metastases. Dr. Katz has received research grants from numerous societies, in addition to an NIH K08 award and an NIH COBRE project. He is a member of numerous professional societies, is a reviewer for numerous scientific and clinical journals, and serves on the editorial boards for the Journal of Surgical Research and Cancer Gene Therapy.

steven-r

Steven C. Rose, MD, FSIR

University of California San Diego Health Sciences
steven-r

Steven C. Rose, MD, FSIR
University of California San Diego Health Sciences

Dr. Rose is currently a Professor of Clinical Radiology at the University of California San Diego Health Sciences, where he has practiced for more than 20 years as the Section Chief of Interventional Oncology. His practice is focused primarily on Interventional Oncology but also includes the spectrum of Vascular and Interventional Radiology.

Before joining UCSD in 1994, Dr. Rose had prior Academic Appointments at Duke University, the University of Utah Medical Center, the University of California, Los Angeles as well as the Virginia Mason Clinic. He has served in numerous leadership roles for the Society of Interventional Radiology and the Western Angiographic and Interventional Society. In addition, Dr. Rose has served as a Grant Reviewer for several national organizations including the National Institute of Health.

Dr. Rose has authored more than 200 peer-reviewed articles, book chapters and abstracts for leading medical journals including the Journal of Vascular and Interventional Radiology. He is a Fellow of the Society of Interventional Radiology, a Fellow of the American Heart Association and a Corresponding Fellow of the Cardiovascular and Interventional Radiology Society of Europe.

Dr. Rose received his Bachelor of Arts degree in Biology from Whitman College and his Doctorate of Medicine from the University of Washington School of Medicine. He completed his residency in Diagnostic Radiology and fellowship in Angiography at the University of Colorado Health Sciences.